Mimix™ Prostate Cancer Panel, FFPE Reference Standard

This Revvity Mimix reference standard is the FFPE version of the Prostate Cancer Panel cfDNA Reference Standard (HD836). This reference material resembling clinical (FFPE) samples can be used for end-to-end validation of molecular assays designed for testing prostate cancer specific mutations.

Product name change
As part of the continuous evolution of our portfolio, we have changed the name of our range to Mimix™ reference standards to better reflect the patient-like performance they provide.

While our product range has a new name, everything you rely on remains the same:

  • Identical formulation and performance
  • Same part numbers and SKUs
  • Existing protocols and procedures
  • Same technical specifications
  • Quality and reliability you trust

No action is required from you. Future orders, product labels, documentation, and communications will reference the new product name.

The Prostate Cancer Panel FFPE Reference Standard is a well-characterized, cell line-derived control material manufactured under ISO:13485 that contains 16 variants across 9 genes clinically relevant to prostate cancer. This innovative, multigene multiplex product allows labs to perform fast, reliable, and cost-effective validation of prostate cancer assays using FFPE samples, saving the user time and money to achieve their quality assurance goals faster. Additionally, it allows the user to assess the performance of FFPE-based assays crucial for routine clinical diagnostics. Like all Revvity Mimix reference standards, it closely mimics patient samples used in diagnostic workflows.

Batch-specific supplementary NGS data

The Prostate Cancer Panel FFPE Reference Standard comes with a batch specific supplementary NGS data. You can access the VCF file here. Each batch was sequenced using Agilent's CREV4 (Clinical Research Exome) kit at a depth of 250x on Illumina platform and run through the Illumina DRAGEN Somatic Pipeline for mapping, sorting, and variant calling.

 

Technical Data

Format: FFPE

Fixation Method: 4% PFA (w/v)

Section Size: 15µm

Cell Density: 3 x 108 cells per block. Approx. 3.5  x 105 cells per section

Expected DNA Yield: 400 ng using Promega Maxwell RSC FFPE Plus DNA Extraction kit

Genes covered: AR, BRCA1, BRCA2, CDKN2A, PIK3CA, PTEN, RB1, STK11, TP53

Allelic Frequencies: 2.50- 11.00%

Verified Mutations: 

Gene DNA sequence
change		 Amino acid change Expected
allelic frequency (%)
AR c.2623C>T p.H875Y 2.50
AR c.2632A>G p.T878A 2.50
BRCA1 c.5329dup p.Q1777Pfs*74 6.50
BRCA2 c.9924C>G p.Y3308* 6.00
CDKN2A c.250G>T p.D84Y 7.00
PIK3CA c.1637A>G p.Q546R 6.00
PIK3CA c.1624G>A p.E542K 8.00
PTEN c.17_18del p.K6Rfs*4 4.00
RB1 c.2143A>T p.K715* 7.00
STK11 c.532_536del p.K178fs*86 10.00
TP53 c.992A>G p.Q331R 7.00
TP53 c.742C>T p.R248W 11.00
TP53 c.668C>T p.P223L 4.00
TP53 c.820G>T p.V274F 8.00
TP53 c.414del p.K139Rfs*31 8.00
AR CNV-Gain N/A 5.00 copies

 

General information

Storage:  4°C

Shipping:  Ambient

Expiration:  See all product shelf life information

 

Quality control

Allelic frequency:  Droplet Digital™ PCR

Quantification:  Quantifluor

DNA Integrity:  Agarose gel electrophoresis

Manufacturing Quality:  ISO 9001:2015 and ISO 13485:2016

Intended use: For assay developers and molecular diagnostic labs for routine performance monitoring of molecular biology assays. Research use only. Not for diagnostic procedures.